The idea behind Glucox Biotech’s diabetes therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species and thus improve blood glycemic control and also decrease the critical risks and delay progression of complications in type 2 patients. Reducing Oxidative Stress at the Source Glucox Biotech AB activity focuses on developing pharmaceutical treatments, targeting specific sources of reactive oxygen that causes oxidative stress in diabetes with its complications, based on the company’s proprietary rights covering the rights to develop pharmaceutical substances for treating disorders related to oxidative stress on the basis of reactive oxygen species produces by NAD(P)H-oxidase, primarily NOX4. Recent literature establishes NOX4 as an important factor in stroke. Therefore, Glucox Biotech also develops NOX4 inhibitors for the treatment of stroke. Glucox Biotech owns several patents covering the exclusive rights to develop pharmaceutical substances for treating insulin resistance and diabetes on the basis of reducing reactive oxygen species produces by NAD(P)H-oxidase (NOX4). --------------------------------------------------------------------------------------------------------------------------------------------- December 20, 2012 Agreement with Accelera Glucox Biotech has signed an agreement with Accelera Srl, Milano, Italy. Accelera will evaluate pharmacokinetics and time course of brain uptake of Glucox' lead compounds in mice. --------------------------------------------------------------------------------------------------------------------------------------------- December 15, 2012 SMURF grant to Glucox and Prof. Nils Welsh Uppsala University and SLU have together with the European Regional Development Fund allotted Glucox Biotech and Professor Nils Welsh a SMURF grant for further studies of the protective action of Glucox´ lead compounds on beta cells. --------------------------------------------------------------------------------------------------------------------------------------------- July 2, 2012 Agreement with Maastricht University Glucox Biotech has signed an agreement with Prof. Harald Schmidt of Maastrich University for further development of Glucox´ lead compound for treatment of ischemic stroke. Read more --------------------------------------------------------------------------------------------------------------------------------------------- June 10, 2012 Agreement with Karolinska Institutet Glucox Biotech has signed an agreement with Prof. Anders Arner of Karolinska Institutet for further studies of Glucox´ NOX4 smal molecule inhibitors in diabetic models. --------------------------------------------------------------------------------------------------------------------------------------------- February 9, 2012 X. Wu and coworkers show importance of NOX4 in insulin resistance "NOX4 pathway as a source of selectivite insulin resistance and responsiveness" Ref: Wu, X., et al (2012) Arterioscler Thromb Vasc Biol. 2012 Feb 9. (Epubl ahead of print) -------------------------------------------------------------------------------------------------------------------------------------------- November 20, 2011 New publication from Glucox Biotech and academic partners "Shikonin increases glucose uptake in skeletal muscle cells and improves plasma glucose levels in diabetic Goto-Kakizaki rats". Ref: Öberg, A.I., et al (2011) PLoS One, 6 (7): e22510 October 03, 2011 Agreement with Redoxis AB --------------------------------------------------------------------------------------------------------------------------------------------- March 14, 2011 Agreement with Department of Pharmacy, Uppsala University Glucox Biotech annnounces the signing of an agreement with Department of Pharmacy, Uppsala University for the further characterization of Glucox' small molecule inhibitors of NOX4. --------------------------------------------------------------------------------------------------------------------------------------------- December 22, 2010 Agreement with Redoxis AB Glucox Biotech announces the signing of a contract with Redoxis AB for further studie on Glucox smal molecule NOX4 inhibitors. --------------------------------------------------------------------------------------------------------------------------------------------- August 29, 2010 Change of CEO Erik Walum has been appointed new CEO of Glucox Biotech. Mona Wilcke is the new Chair of Board of Directors --------------------------------------------------------------------------------------------------------------------------------------------- April 29, 2010 Approval of patent in Europe Glucox Biotech has been approved its third patent application in Europe in April 2010. | company. On the basis of a favourable patent position, extensive experience in the development of medicines for metabolic diseases, and in collaboration with academic researchers and contract research organisations Glucox Biotech develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. Glucox Biotech also explores new ideas for the prevention of neuronal damage in ischemic stroke.  |
Home |